GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

GSK is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 8.62; value investors should ...

For new and old investors, taking full advantage of the stock market and investing ... its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, ...

The fallers board was led by WPP, which slumped by 16% to its lowest level since 2009 after the marketing and advertising ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

Hindustan Unilever naming Priya Nair as MD and chief executive officer receives a big thumbs up from investors as stocks gain despite market slump, but there are many challenges to address for the FMC ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

European stocks ended the week with a small decline, as GSK Plc’s shares weighed on the healthcare sector on a busy earnings day.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain ...